<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3006222294
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2004
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        XEFO 8MG Powder for injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LORNOXICAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        8
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and solvent for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        15.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="TAKEDA AUSTRIA GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            TAKEDA AUSTRIA GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AC05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Xefo is a non-steroidal anti-inflammatory drug (NSAID) and antirheumatic drug of the oxicam class. It is intended for adults for;</p><ul><li>Short-term symptomatic treatment of acute mild to moderate pain when oral administration is inappropriate.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Xefo </strong></p><ul><li>If you are allergic to lornoxicam or any of the other ingredients of this medicine (listed in section&nbsp;6);</li><li>If you are hypersensitive to other NSAIDs including acetylsalicylic acid (for instance, aspirin);</li><li>If you suffer from thrombocytopenia (low blood platelet count which increases risk of bleeding or bruising);</li><li>If you suffer from severe heart failure;</li><li>If you suffer from gastrointestinal bleeding, rupture and bleeding of a blood vessel in the brain, or other bleeding disorders;</li><li>If you have a history of gastrointestinal bleeding or perforation, related to previous therapy with NSAIDs;</li><li>If you suffer from an active peptic ulcer or have a history of recurrent peptic ulcer;</li><li>If you suffer from severe liver impairment;</li><li>If you suffer from severe kidney impairment;</li><li>If you are in the last three months of your pregnancy.</li></ul><p><strong>Warnings and precautions</strong><br />Talk to your doctor or pharmacist before taking Xefo. This is particularly important:</p><ul><li>If you have impaired kidney function;</li><li>If you have a history of high blood pressure and/or heart failure;</li><li>If you suffer from ulcerative colitis or Crohn&rsquo;s disease;</li><li>If you have a history of bleeding tendency;</li><li>If you have a history of asthma;</li><li>If you suffer from SLE (lupus erythematosus, a rare immunological disease).</li></ul><p>Your doctor may have to monitor you by laboratory tests on a frequent basis if:</p><ul><li>You suffer from blood coagulation disorder;</li><li>You suffer from impaired liver function;</li><li>You are elderly;</li><li>Or you will be treated with Xefo for more than 3&nbsp;months.</li></ul><p>You should inform your doctor if you are going to be treated with heparin or tacrolimus, while taking at the same time Xefo.</p><p>If you experience any unusual abdominal symptoms such as abdominal bleeding, skin reactions such as skin rash, damage to the internal lining of the nostrils, mouth, eyelids, ears, genitals or anus, or other signs of hypersensitivity, you should stop taking Xefo and contact your doctor immediately.</p><p>Medicines such as Xefo may be associated with a small increase of the risk of heart attack (myocardial infarction) or stroke. Any risk is more likely with high doses and prolonged treatment. Do not exceed the recommended dose or the duration of treatment.</p><p>You should discuss your treatment with your doctor or pharmacist if:</p><ul><li>You have heart problems;</li><li>You had previously a stroke;</li><li>Or you think that you might be at risk of developing these conditions (for example, if you have high blood pressure, diabetes or high cholesterol, or you are a smoker).</li></ul><p>Avoid using Xefo during varicella (chickenpox) infections.</p><p><strong>Other medicines and Xefo</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>You should avoid using Xefo if you are taking other NSAIDs such as acetylsalicylic acid (for instance, aspirin), ibuprofen and COX-2 inhibitors.</p><p>Xefo may interfere with other medicines. Be particularly careful if you are taking any of the following:</p><ul><li>Cimetidine - used in the treatment of heartburn and peptic ulcers;</li><li>Anticoagulants, such as warfarin, heparin or phenprocoumon - used to prevent the formation of blood clots;</li><li>Corticosteroids;</li><li>Methotrexate - used in treatment of cancer and immunological diseases;</li><li>Lithium;</li><li>Immunosuppresive agents, such as ciclosporine or tacrolimus;</li><li>Heart medicines, such as digoxin, ACE-inhibitors, beta-adrenergic blockers;</li><li>Diuretics;</li><li>Quinolone antibiotics (e.g. levofloxacin, ofloxacin);</li><li>Anti-platelet agents (e.g. clopidogrel) - medicines used to prevent heart attacks and strokes;</li><li>SSRI (Selective Serotonin Reuptake Inhibitors) &ndash; used in the treatment of depression;</li><li>Sulphonylureas, for instance glibenclamide - used in the management of diabetes;</li><li>Inducers and inhibitors of CYP2C9-isoenzymes (such as the antibiotic rifampicin or the antifungal medicine fluconazole), as they might have an effect on the way in which your body breaks down Xefo;</li><li>Angiotensin II receptor blocker - used to treat high blood pressure, kidney damage due to diabetes and congestive heart failure;</li><li>Pemetrexed - used to treat some forms of lung cancer.</li></ul><p><strong>Pregnancy, breast-feeding and fertility</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><em>Fertility</em><br />Using Xefo may impair fertility and is not recommended for women attempting to become pregnant. Women who have difficulties becoming pregnant, or who are undergoing investigation of infertility, should consult with a doctor and consider stopping treatment with Xefo.</p><p><em>Pregnancy</em><br />During the first 6&nbsp;months of pregnancy treatment with Xefo is not recommended, unless explicitly advised by your doctor.</p><p>You must not take Xefo during the last three months of your pregnancy.</p><p><em>Breast-feeding</em><br />If you are breast-feeding treatment with Xefo is not recommended, unless explicitly advised by your doctor.</p><p><strong>Driving and using machines</strong><br />Xefo has negligible or no influence on the ability to drive or use machinery.</p><p><strong>Xefo<strong> </strong>contains sodium</strong><br />Xefo contains sodium. Each vial of Xefo 8 mg Powder for Solution for Injection contains 0.027 mg sodium. This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially &lsquo;sodium-free&rsquo;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose for adults is 8 mg intramuscular (i.m.) or intravenous (i.v.).</p><p>You should not receive more than 16 mg a day. However, on the first day of treatment, your doctor may have to prescribe for you an additional dose of 8 mg of Xefo solution for injection.</p><p>Xefo 8 mg Powder for Solution for Injection must be dissolved with the accompanying 2 ml solvent for solution for injection before use.</p><p>Xefo 8 mg Solution for Injection is intended for intramuscular (i.m.) or intravenous (i.v.) injection. The injection should be administered slowly, over not less than 15 seconds as an i.v. injection, and over not less than 5 seconds as i.m. injection.</p><p>Do not mix Xefo 8 mg Solution for Injection with other medicinal products, unless compatibility is clearly proven. Lornoxicam has shown compatibility with 0.9% NaCl, 5% dextrose (glucose) and Ringer&rsquo;s solution. If compatibility is not clearly proven, Xefo 8 mg Solution for Injection should always be administered separately.</p><p><strong>If you use more Xefo than you should</strong><br />Please contact your doctor or the pharmacist if you have taken more Xefo than prescribed.</p><p>In case of an overdose, you may expect the following symptoms: nausea, vomiting, symptoms associated with central nervous system (such as dizziness or disturbances in vision). Severe symptoms such as ataxia (ascending to coma and cramps), liver and kidney damage and potentially coagulation disorders may also occur.</p><p><strong>If you forget to use Xefo</strong><br />Do not ask for a double dose to make up for a forgotten dose.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Medicines such as Xefo may be associated with a small increase in the risk of heart attack or stroke.</p><p>If you experience any unusual abdominal symptoms such as abdominal bleeding, skin reactions such as skin rash, damage to the internal lining of the nostrils, mouth, eyelids, ears, genitals or anus, or other signs of hypersensitivity, you should stop taking Xefo and contact your doctor immediately.</p><p>If you get any of the following side effects, stop taking this medicine and tell your doctor immediately, or contact the emergency department at your nearest hospital:</p><ul><li>Shortness of breath, chest pains, or ankle swelling appear or get worse;</li><li>Severe or continuous stomach pain or your stools become black;</li><li>Yellowing of the skin and eyes (jaundice) &ndash; these are signs of liver problems;</li><li>An allergic reaction - which can include skin problems such as ulcers or blistering, or swelling of the face, lips, tongue, or throat which may cause difficulty in breathing;</li><li>Fever, blistering eruption or inflammation especially on hands and feet or in the mouth area (Stevens-Johnson syndrome);</li><li>Exceptionally, serious infections of the skin in case of varicella (chickenpox).</li></ul><p>Undesirable effects associated with using Xefo are given below.</p><p><strong>Common</strong><strong> side effects (may affect up to 1 in 10&nbsp;people)</strong></p><ul><li>Mild and passing headache and dizziness;</li><li>Nausea, abdominal pain, upset stomach, diarrhoea and vomiting.</li></ul><p><strong>Uncommon side effects (may affect up to 1 in 100&nbsp;people)</strong></p><ul><li>Weight loss (anorexia), inability to sleep (insomnia), depression;</li><li>Eye discharges (conjunctivitis);</li><li>Feeling dizzy, ringing in the ears (tinnitus);</li><li>Cardiac failure, irregular heartbeat, rapid heart rate, feeling blushed;</li><li>Constipation, excessive wind (flatulence), belching, dry mouth, gastritis, peptic ulcer, upper abdominal pain, duodenal ulcer, mouth ulcers;</li><li>Increase in liver function tests (as seen from blood tests) and feeling unwell (malaise);</li><li>Rash, itching, increased sweating, redness of the skin (erythema), angiooedema (rapid swelling of the deeper layers of skin, usually of the face), hives (urticaria), oedema, stuffy nose as a result of an allergy (rhinitis);</li><li>Hair loss (alopecia);</li><li>Pain in the joints (arthralgia).</li></ul><p><strong>Rare side effects (may affect up to 1 in 1,000&nbsp;people)</strong></p><ul><li>Sore throat;</li><li>Anaemia, reduction in the blood cell count (thrombocytopenia and leucopenia), weakness;</li><li>Hypersensitivity, including anaphylactoid reaction and anaphylaxis (organism reaction characterized usually by face swelling, flushing, difficulties breathing and lightheadedness);</li><li>Confusion, nervousness, agitation, feeling sleepy (somnolence), paraesthesia (tingling sensations), abnormal sense of taste, tremor, migraine, visual disturbances;</li><li>Elevated blood pressure, hot flush;</li><li>Bleeding, haematoma (bruising), prolonged bleeding time;</li><li>Difficulty in breathing (dyspnoea), cough, bronchospasm;</li><li>Perforated ulcer, vomiting of blood, gastrointestinal bleeding, black tarry stools;</li><li>Inflammation in the mouth, oesophagitis (inflammation of the gullet), gastro-oesophageal reflux, difficulty in swallowing, aphthous stomatitis (ulcers), inflammation of the tongue;</li><li>Abnormal liver function;</li><li>Skin problems, such as eczema, rash;</li><li>Bone pain, muscle cramp, muscle pain;</li><li>Urinary problems, such as the need to wake up and urinate during the night (nocturnia) or an increase in the levels of urea and creatinine in the blood.</li></ul><p><strong>Very rare side effects (may affect up to 1 in 10,000&nbsp;people)</strong></p><ul><li>Liver damage, hepatitis (inflammation of the liver), jaundice, cholestasis (interrupted flow of bile from the liver);</li><li>Bruising, oedema, severe skin disorder (Stevens-Johnson syndrome, toxic epidermal necrolysis);</li><li>Aseptic meningitis;</li><li>NSAID class effects: neutropenia, agranulocytosis, aplastic anaemia, haemolytic anaemia, kidney toxicity</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 25&deg;C.</p><p>Store in the original package in order to protect from light.</p><p>The chemical and physical in-use stability has been demonstrated for 24&nbsp;hours at 21&deg;C (&plusmn;2&deg;C).</p><p>From a microbiological point of view, the product should be used immediately. If the solution is not used immediately, in-use storage times and conditions prior to use is the responsibility of the user and would not be longer than 24&nbsp;hours at 2-8&deg;C, unless reconstitution/dilution has taken place in controlled and validated aseptic condition.</p><p>Do not use this medicine after the expiry date which is stated on the package &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>If visible signs of deterioration are seen in this medicinal product, the product must be disposed of in accordance with local requirements.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is lornoxicam.</p><p>Each vial of Xefo 8 mg Powder for Solution for Injection contains 8 mg lornoxicam.</p><p>After reconstitution, each ml contains 4 mg lornoxicam.</p><p>The other ingredients are: <em>Powder</em> <em>(vial):</em> Mannitol, trometamol and disodium edetate. <em>Solvent</em> <em>(ampoule):</em> Water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Xefo 8 mg Powder and Solvent for Solution for Injection consists of: 
Powder: Is a yellow, solid substance in amber glass (class I) vials with rubber stoppers, sealed with aluminium snap-off closures. 

Solvent: Is a clear liquid in clear glass ampoules. 

After reconstitution, the solution for injection is a yellow, clear liquid. 

Pack size: 1 Vial + 1 Ampoule (2 ml water for injection).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong><br />Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. Box 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p><strong>Bulk manufacturer</strong><br />Wasserburger Arzneimitttelwerk GmbH<br />Herderstra&beta;e 1, 2 and Molkerei-Bauer-Stra&beta;e 18<br />83512 Wasserburg<br />Germany</p><p><strong>Under licensed from</strong><br />Takeda Austria GmbH<br />St. Peter-Stra&szlig;e 25<br />4020 Linz<br />Austria</p><p><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 02/2023; version number SA2.1.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">زيفو هو عقار مضاد للالتهابات غير الستيرويدية ومضاد للروماتيزم من فئة أوكسيكام. وهو عقار مخصص للبالغين من أجل؛</p><ul dir="rtl"><li>علاج قصير المدى لأعراض الألم الحاد الخفيف إلى المتوسط عندما يكون تناول العلاج عن طريق الفم غير ملائم.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم زيفو </strong></p><ul dir="rtl"><li>إذا كنت تعاني من حساسية للورنوكسيكام أو لأي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم 6)؛</li><li>إذا كنت تعاني من حساسية مفرطة تجاه مضادات الالتهاب غير الستيرويدية الأخرى بما في ذلك حمض الأسيتيل ساليسيليك (على سبيل المثال، الأسبرين)؛</li><li>إذا كنت تعاني من قلّة الصفيحات (انخفاض عدد الصفائح الدموية الذي يزيد من خطر النزف أو التكدم)؛</li><li>إذا كنت تعاني من فشل قلبي شديد؛</li><li>إذا كنت تعاني من نزف معدي معوي، تمزق ونزف أحد الأوعية الدموية في المخ، أو اضطرابات نزفية أخرى؛</li><li>إذا كان لديك تاريخ للإصابة بنزف معدي معوي أو انثقاب، مرتبط بعلاج سابق باستخدام مضادات الالتهاب غير الستيرويدية؛</li><li>إذا كنت تعاني من قرحة معدية نشطة أو لديك تاريخ للإصابة بقرحة معدية متكررة؛</li><li>إذا كنت تعاني من قصور شديد في الكبد؛</li><li>إذا كنت تعاني من قصور شديد في الكُلى؛</li><li>إذا كنتِ في الأشهر الثلاثة الأخيرة من الحمل.</li></ul><p dir="RTL"><strong>الاحتياطات والتحذيرات&nbsp;</strong><br />تحدث مع طبيبك أو الصيدلي قبل استخدام زيفو. وتزداد أهمية هذا في الحالات التالية:</p><ul dir="rtl"><li>إذا كنت مصاباً بقصور في وظيفة الكُلى؛</li><li>إذا عانيت في السابق من ارتفاع ضغط الدم و/أو فشل القلب.</li><li>إذا كنت تعاني من التهاب القولون التقرحي أو داء كرون؛</li><li>إذا كانت لديك في السابق قابلية للنزف؛</li><li>إذا كنت مصاباً في السابق بالربو؛</li><li>إذا كنت تعاني من الذئبة الحمامية المجموعية (الذئبة الحمامية، مرض مناعي نادر).</li></ul><p dir="RTL">قد يتوجب على طبيبك مراقبتك من خلال افحوصات المختبر بشكل متكرر إذا:</p><ul dir="rtl"><li>كنت تعاني من اضطراب تخثر الدم؛</li><li>كنت تعاني من قصور في وظيفة الكبد؛</li><li>كنت من كبار السن؛</li><li>أو سيتم علاجك باستخدام زيفو لأكثر من 3&nbsp;أشهر.</li></ul><p dir="RTL">يجب عليك إبلاغ طبيبك إذا كنت ستخضع للعلاج باستخدام هيبارين أو تاكروليموس، بينما تستخدم زيفو في الوقت نفسه.</p><p dir="RTL">إذا عانيت من أي أعراض غير معتادة في البطن مثل نزف البطن، ردود فعل جلدية مثل الطفح الجلدي، تلف في البطانة الداخلية للمناخير، الفم، الجفون، الأذنين، الأعضاء التناسلية أو الشرج، أو أعراض فرط حساسية أخرى، فيجب عليك التوقف عن استخدام زيفو والاتصال بالطبيب على الفور.</p><p dir="RTL">قد يرتبط استخدام أدوية مثل زيفو بحدوث زيادة بسيطة في احتمال الإصابة بأزمة قلبية (احتشاء عضلة القلب) أو سكتة دماغية. ويزداد أي خطر مع الجرعات الأعلى والعلاج لمدة طويلة. لا تتجاوز الجرعة أو مدة العلاج المُوصى بها.</p><p dir="RTL">يجب عليك مناقشة علاجك مع طبيبك أو الصيدلي إذا:</p><ul dir="rtl"><li>كنت تعاني من مشاكل في القلب؛</li><li>تعرضت لسكتة دماغية من قبل؛</li><li>أو كنت تعتقد أنك ربما تكون معرضاً لخطر الإصابة بهذه الحالات (على سبيل المثال، إذا كنت تعاني مثلاً من ارتفاع ضغط الدم، السكري أو ارتفاع مستوى الكوليسترول، أو كنت مدخن).</li></ul><p dir="RTL">تجنب استخدام زيفو أثناء الإصابة بعدوى الحماق (جدري الماء).</p><p dir="RTL"><strong>الأدوية الأخرى وزيفو&nbsp;</strong><br />أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخراً، أو قد تتناول أية أدوية أخرى.</p><p dir="RTL">يجب عليك تجنب استخدام زيفو بينما تتناول أدوية أخرى من مضادات الالتهابات غير الستيرويدية مثل حمض الأسيتيل ساليسيليك (على سبيل المثال، الأسبرين)، الإيبوبروفين ومثبطات إنزيم سيكلو أكسيجيناز-2.</p><p dir="RTL">قد يتداخل زيفو مع الأدوية الأخرى. توخ الحذر بشكل خاص إذا كنت تتناول أيّاً مما يلي:</p><ul dir="rtl"><li>سيميتيدين - المستخدم لعلاج حرقة المعدة والقرحة المعدية؛</li><li>مضادات التخثر، مثل الوارفارين، الهيبارين أو الفينبروكومون - المستخدمة لمنع تكوّن الجلطات الدموية؛</li><li>الستيرويدات القشرية؛</li><li>ميثوتركسيت - المستخدم لعلاج السرطان والأمراض المناعية؛</li><li>الليثيوم؛</li><li>العوامل المثبطة للمناعة، مثل سيكلوسبورين أو تاكروليموس؛</li><li>أدوية القلب، مثل ديجوكسين، مثبطات الإنزيم المحول للأنجيوتنسين، وحاصرات بيتا الأدرينالية؛</li><li>مدرات البول؛</li><li>مضادات الكوينولون الحيوية (مثل، الليڤوفلوكساسين، أوفلوكساسين)؛</li><li>عوامل مضادات الصفيحات (مثل، كلوبيدوجريل) - أدوية مستخدمة للوقاية من الأزمات القلبية والسكتات الدماغية؛</li><li>مثبطات استرداد السيروتونين الانتقائية - المستخدمة في علاج الاكتئاب؛</li><li>السلفونيليوريا، مثل جليبنكلاميد - المستخدم في علاج مرض السكري؛</li><li>محفزات ومثبطات نظائر الإنزيم سيتوكروم-CYP2C9 (مثل المضاد الحيوي ريفامبيسين أو الدواء المضاد للفطريات فلوكونازول)، حيث قد يكون لها تأثير على الطريقة التي يحلل بها جسمك زيفو؛</li><li>حاصر مستقبل أنجيوتنسين II - المستخدم لعلاج ارتفاع ضغط الدم، تلف الكُلى بسبب مرض السكري وفشل القلب الاحتقاني؛</li><li>بيميتريكسيد - المستخدم لعلاج بعض أشكال سرطان الرئة.</li></ul><p dir="RTL"><strong>الحمل، الرضاعة والخصوبة&nbsp;</strong><br />اطلبي النصيحة من طبيبك أو الصيدلي قبل استخدام هذا الدواء إذا كنت حاملاً أو مرضعاً، تعتقدين بأنك حاملاً أو تخططين لذلك.</p><p dir="RTL"><em>الخصوبة&nbsp;</em><br />قد يضعف استخدام زيفو الخصوبة ولا يُنصح باستخدامه لدى السيدات اللاتي يخططن للحمل. يجب على السيدات اللاتي يعانين من صعوبات في الحمل أو يخضعن لفحوصات العقم استشارة أحد الأطباء والنظر في إيقاف العلاج باستخدام زيفو.</p><p dir="RTL"><em>الحمل&nbsp;</em><br />لا يوصى بالعلاج باستخدام زيفو خلال الأشهر الستة الأولى من الحمل، ما لم ينصح به طبيبك صراحة.</p><p dir="RTL">يجب عليكِ عدم استخدام زيفو خلال الأشهر الثلاثة الأخيرة من الحمل.</p><p dir="RTL"><em>الرضاعة الطبيعية&nbsp;</em><br />لا يوصى بالعلاج باستخدام زيفو إذا كنتِ ترضعين رضاعة طبيعية، ما لم ينصح به طبيبك صراحة.</p><p dir="RTL"><strong>القيادة واستخدام الآلات&nbsp;</strong><br />يمتلك زيفو تأثيراً ضئيلاً أو منعدماً على القدرة على القيادة أو استخدام الآلات.</p><p dir="RTL"><strong>يحتوي زيفو على الصوديوم&nbsp;</strong><br />يحتوي زيفو على الصوديوم. تحتوي كل زجاجة من زيفو 8 ملغم مسحوق للحل للحقن على 0.027 ملغم صوديوم. يحتوي هذا الدواء على أقل من 1 ملمول صوديوم (23 ملغم) لكل زجاجة، بمعنى أنه &rsquo;خالٍ من الصوديوم&lsquo; بشكل أساسي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قم دائماً باستخدام دوائك كما أخبرك طبيبك تماماً. تحقق من طبيبك أو الصيدلي إذا لم تكن متأكداً.</p><p dir="RTL">الجرعة الموصى بها للبالغين هي 8 ملغم في العضل أو في الوريد.</p><p dir="RTL">يجب ألا تستخدم أكثر من 16 ملغم في اليوم. ومع ذلك، قد يضطر طبيبك إلى وصف جرعة إضافية بمقدار 8 ملغم من زيفو محلول للحقن في اليوم الأول من العلاج.</p><p dir="RTL">تجب إذابة زيفو 8 ملغم مسحوق للحل للحقن باستخدام 2 مللتر من المذيب المرافق لإعداد محلول للحقن قبل الاستخدام.</p><p dir="RTL">زيفو 8 ملغم محلول للحقن مخصص للحقن في العضل أو في الوريد. يجب إعطاء الحقنة ببطء، خلال ما لا يقل عن 15 ثانية كحقنة وريدية، وما لا يقل عن 5 ثوانٍ كحقنة عضلية.</p><p dir="RTL">لا تخلط زيفو 8 ملغم محلول للحقن مع أي مستحضرات دوائية أخرى، ما لم يثبت التوافق بوضوح. لقد ثبت توافق لورنوكسيكام مع 0.9% كلوريد الصوديوم، 5% دكستروز (جلوكوز) ومحلول رينغر. إذا لم يتم إثبات التوافق بوضوح، فيجب دائماً إعطاء زيفو 8 ملغم محلول للحقن على حدة.</p><p dir="RTL"><strong>إذا استخدمت زيفو أكثر من اللازم&nbsp;</strong><br />يرجى الاتصال بطبيبك أو الصيدلي إذا استخدمت زيفو أكثر من الجرعة الموصوفة.</p><p dir="RTL">في حالة تناول جرعة زائدة، يمكنك توقع الأعراض التالية: غثيان، قيء، أعراض مرتبطة بالجهاز العصبي المركزي (مثل الدوار أو اضطرابات الرؤية). قد تحدث أيضاً أعراض شديدة&nbsp; مثل الرنح (قد يتفاقم إلى غيبوبة وتشنجات)، تلف الكبد والكُلى واضطرابات التخثر المحتملة.</p><p dir="RTL"><strong>إذا نسيت استخدام زيفو&nbsp;</strong><br />لا تطلب الحصول على جرعة مضاعفة لتعويض جرعة منسية.</p><p dir="RTL">إذا كان لديك أي أسئلة إضافية حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبيةً، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL">قد يرتبط تناول أدوية مثل زيفو بحدوث زيادة بسيطة في خطر الإصابة بأزمة قلبية أو سكتة دماغية.</p><p dir="RTL">إذا عانيت من أي أعراض غير معتادة في البطن مثل نزف البطن، ردود فعل جلدية مثل الطفح الجلدي، تلف في البطانة الداخلية للمناخير، الفم، الجفون، الأذنين، الأعضاء التناسلية أو الشرج، أو أعراض فرط حساسية أخرى، فيجب عليك التوقف عن تناول زيفو والاتصال بطبيبك على الفور.</p><p dir="RTL">إذا أصبت بأي من الآثار الجانبية التالية، توقف عن تناول هذا الدواء وأخبر الطبيب فوراً أو اتصل بقسم الطوارئ في أقرب مستشفى منك:</p><ul dir="rtl"><li>ضيق النفس، آلام الصدر، أو تورم الكاحل أو ازدياده سوءاً؛</li><li>ألم المعدة الشديد أو المستمر أو يصبح البراز أسود؛</li><li>اصفرار الجلد والعينين (اليرقان) - هذه علامات الإصابة بمشاكل في الكبد؛</li><li>رد فعل تحسسي - قد يشمل مشاكل جلدية مثل القرح أو البثور، أو تورم الوجه، الشفتين، اللسان، أو الحلق ما قد يؤدي إلى صعوبة في التنفس؛</li><li>الحمى، ظهور البثور أو الالتهاب خاصة في اليدين والقدمين أو منطقة الفم (متلازمة ستيفنز جونسون)؛</li><li>بشكل استثنائي، العدوى الخطيرة بالجلد في حالة الحماق (جدري الماء).</li></ul><p dir="RTL">يرد فيما يلي ذكر التأثيرات غير المرغوبة المرتبطة باستخدام زيفو.</p><p dir="RTL"><strong>آثار جانبية شائعة (قد تؤثر فيما يصل إلى شخص من بين كل 10&nbsp;أشخاص)</strong></p><ul dir="rtl"><li>صداع خفيف وعابر ودوار؛</li><li>غثيان، ألم في البطن، اضطراب المعدة، إسهال وقيء.</li></ul><p dir="RTL"><strong>آثار جانبية غير شائعة (قد تؤثر فيما يصل إلى شخص من بين كل 100&nbsp;شخص)</strong></p><ul dir="rtl"><li>فقدان الوزن (فقدان الشهية)، عدم القدرة على النوم (الأرق)، اكتئاب؛</li><li>إفرازات العين (التهاب الملتحمة)؛</li><li>شعور بالدوار، طنين في الأذنين (طنين)؛</li><li>فشل القلب، عدم انتظام ضربات القلب، سرعة ضربات القلب، شعور باحمرار الوجه؛</li><li>إمساك، زيادة الغازات (الانتفاخ)، تجشؤ، جفاف الفم، التهاب المعدة، قرحة هضمية، ألم في الجزء العلوي من البطن، قرحة الاثني عشر، قرح الفم؛</li><li>زيادة في فحوصات وظائف الكبد (كما يظهر من فحوصات الدم) وشعور بالتعب (توعك)؛</li><li>طفح جلدي، حكة، زيادة التعرق، احمرار الجلد (الحمامي)، وذمة وعائية (تورم سريع في الطبقات العميقة للجلد، عادة في الوجه)، شرى (إرتكاريا)، وذمة، انسداد الأنف نتيجة للحساسية (التهاب الأنف)؛</li><li>تساقط الشعر (الثعلبة)؛</li><li>ألم في المفاصل (ألم مفصلي).</li></ul><p dir="RTL"><strong>آثار جانبية نادرة (قد تؤثر فيما يصل إلى شخص من بين كل 1000&nbsp;شخص)</strong></p><ul dir="rtl"><li>التهاب الحلق؛</li><li>فقر الدم، انخفاض عدد خلايا الدم (قلّة الصفيحات وقلّة كريات الدم البيضاء)، ضعف؛</li><li>فرط الحساسية، بما في ذلك رد فعل تأقي والتأق (رد فعل عضوي يتسم عادة بتورم الوجه، احمراره، صعوبات في التنفس والدوار)؛</li><li>تشوش، عصبية، تهيج، شعور بالنعاس (نيمومة)، مذل (إحساس بالوخز)، تغير المذاق، رعاش، صداع نصفي، اضطرابات بصرية؛</li><li>ارتفاع ضغط الدم، هبات الحرارة؛</li><li>نزف، ورم دموي (تكدم)، نزف لفترة طويلة؛</li><li>صعوبة في التنفس (ضيق النفس)، سعال، تشنج قصبي؛</li><li>قرحة مثقوبة، تقيؤ الدم، نزف معدي معوي، براز قطراني أسود؛</li><li>التهاب في الفم، التهاب المريء، ارتجاع معدي مريئي، صعوبة في البلع، التهاب الفم القلاعي (قرح)، التهاب اللسان؛</li><li>وظائف كبد غير طبيعية؛</li><li>مشاكل جلدية، مثل الإكزيما، طفح جلدي؛</li><li>ألم في العظام، تشنجات في العضلات، ألم في العضلات؛</li><li>مشاكل في المسالك البولية، مثل الحاجة إلى الاستيقاظ والتبول ليلاً أو زيادة مستويات اليوريا والكرياتينين في الدم.</li></ul><p dir="RTL"><strong>آثار جانبية نادرة جداً (قد تؤثر فيما يصل إلى شخص من بين كل 10000&nbsp;شخص)</strong></p><ul dir="rtl"><li>تلف الكبد، التهاب الكبد، اليرقان، الركود الصفراوي (تدفق متقطع للعصارة الصفراوية من الكبد)؛</li><li>تكدم، وذمة، اضطراب حاد في الجلد (متلازمة ستيفنز جونسون، تقشر الأنسجة المتموتة البشروية التسممي)؛</li><li>التهاب السحايا التعقيمي؛</li><li>تأثيرات فئة مضادات الالتهابات غير الستيرويدية: قلة العدلات، ندرة المحببات، فقر الدم اللاتنسجي، فقر الدم الانحلالي، سمية الكُلى</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 25&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الضوء.</p><p dir="RTL">تم إثبات الاستقرار الكيميائي والفيزيائي أثناء الاستخدام لمدة 24&nbsp;ساعة عند درجة حرارة 21&deg; مئوية (&plusmn;2&deg; مئوية).</p><p dir="RTL">من وجهة نظر ميكروبيولوجية، يجب استخدام المستحضر على الفور. في حالة عدم استخدام المحلول على الفور، تقع مسؤولية فترات التخزين أثناء الاستخدام وظروف التخزين قبل الاستخدام على المستخدم ويجب ألا تزيد عادةً عن 24&nbsp;ساعة عند درجة حرارة تتراوح من 2-8&deg; مئوية، ما لم يتم إجراء الحل/التخفيف في بيئة معقمة خاضعة للرقابة والتحقق.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">في حالة ظهور علامات تلف واضحة في هذا المستحضر الدوائي، يجب التخلص من المستحضر وفقاً للمتطلبات المحلية.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية.&nbsp; اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي لورنوكسيكام.</p><p dir="RTL">تحتوي كل زجاجة من زيفو 8 ملغم مسحوق للحل للحقن على 8 ملغم لورنوكسيكام.</p><p dir="RTL">بعد الحل، يحتوي كل مللتر على 4 ملغم لورنوكسيكام.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي: <em>المسحوق</em> (<em>الزجاجة):</em> مانيتول، تروميتامول وإيديتات ثنائي الصوديوم. <em>المذيب</em> (<em>الأمبولة):</em> ماء معد للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">زيفو 8 ملغم مسحوق ومذيب للحل للحقن يتكون من:</p><p dir="RTL"><em>المسحوق:</em> هو<em> </em>مادة صفراء صلبة في زجاجات كهرمانية (الفئة 1) مع سدادات مطاطية، ومحكمة الإغلاق بأغطية كبس من الألومنيوم.</p><p dir="RTL"><em>المذيب:</em> هو سائل صافٍ في أمبولات زجاجية شفافة. &nbsp;</p><p dir="RTL">بعد الحل، يكون محلول الحقن سائل أصفر صافٍ.</p><p dir="RTL">حجم العبوة: زجاجة واحدة + أمبولة واحدة (2 مللتر ماء معد للحقن).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp;اسم وعنوان مالك رخصة التسويق&nbsp;</strong><br />شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>الشركة المصنعة للمستحضر النهائي&nbsp;</strong><br />مصنع واسربورغر الدوائي ذو المسؤولية المحدودة&nbsp;<br />شارع هيردر 1، 2 وشارع مولكيراي-باور 18&nbsp;<br />83512 واسربورغر&nbsp;<br />ألمانيا</p><p dir="RTL"><strong>بترخيص من&nbsp;</strong><br />شركة تاكيدا النمسا ذات المسؤولية المحدودة&nbsp;<br />شارع سانت بيتر 25&nbsp;&nbsp;<br />4020 لينز&nbsp;<br />النمسا</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية&nbsp;</strong><br />تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء. &nbsp;</p><ul dir="rtl"><li>&nbsp;المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي&nbsp;<br />مركز الاتصال الموحد: 19999&nbsp;<br />البريد الإلكتروني: npc.drug@sfda.gov.sa&nbsp;<br />الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><ul dir="rtl"><li>دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 02/2023؛ رقم النسخة SA2.1.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Xefo 8 mg Powder and Solvent for Solution for Injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial of Xefo 8 mg Powder for Solution for Injection contains 8 mg lornoxicam.

Excipient with known effect: Sodium. 

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solvent for solution for injection. 

Powder: Is a yellow, solid substance. 

Solvent: is a clear liquid.  

After reconstitution, the solution for injection is a yellow, clear liquid. 

The osmolarity of the reconstituted solution is about 328 mosmol/kg and pH is about 8.7.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Short-term symptomatic treatment of acute mild to moderate pain in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Posology</em></strong></p><p>This specific pharmaceutical form should only be used if a quick onset of pain relief is needed or if an oral application is not possible. Generally, the treatment should comprise one single injection for therapy initiation only.</p><p>For all patients the appropriate dosing regimen should be based upon individual response to treatment. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4).</p><p><strong>Pain</strong></p><p>Recommended dose: 8 mg for intravenous (IV) or intramuscular (IM) injection. Daily dose should not exceed 16 mg. Some patients may need a further 8 mg given during the first 24 hours.</p><p><strong>Special populations</strong></p><p><em>Paediatric population</em></p><p>Lornoxicam is not recommended for use in children and adolescents below 18 years of age because of a lack of data on safety and efficacy.</p><p><em>Elderly</em></p><p>No special dosage modification is required for elderly patients above 65 years of age unless renal or hepatic function is impaired, but lornoxicam should be administered with caution as gastrointestinal adverse effects are less well tolerated in this group (see section 4.4).</p><p><em>Renal impairment</em></p><p>For patients with mild to moderate renal impairment dose reduction should be considered (see section 4.4). Lornoxicam is contraindicated in patients with severe renal impairment (see section 4.3).</p><p><em>Hepatic impairment</em></p><p>For patients with moderate hepatic impairment dose reduction should be considered (see section 4.4). Lornoxicam is contraindicated in patients with severe hepatic impairment (see section 4.3).</p><p><strong><em>Method of Administration</em></strong></p><p>The medicinal product is for single use only.</p><p>The route of administration is IV or IM injection. When given as IV injection, the time of injection should be at least 15 seconds, and for IM injection, at least 5 seconds.</p><p>After preparation of the solution, the needle should be changed. For IM injection, a sufficiently long needle for a deep intramuscular injection is necessary.</p><p>For further instructions on handling of the product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
•	Thrombocytopenia
•	Hypersensitivity (symptoms like asthma, rhinitis, angioedema or urticaria) to other NSAIDs including acetylsalicylic acid
•	Severe heart failure
•	Gastro-intestinal bleeding, cerebrovascular bleeding or other bleeding disorders
•	History of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy
•	Active or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding)
•	Severe hepatic impairment
•	Severe renal impairment (Serum creatinine > 700 µmol/L) 
•	The third trimester of pregnancy (see section 4.6)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lornoxicam reduces platelet aggregation and prolongs bleeding time. Consequently, caution should be taken when administering to patients with increased bleeding tendency.</p><p>Lornoxicam should only be administered after careful risk-benefit assessment in patients with:&nbsp;</p><ul><li>Renal impairment: lornoxicam should be administered with caution in patients with mild (serum creatinine 150 300 &micro;mol/L) to moderate (serum creatinine 300 700 &micro;mol/L) renal impairment due to dependency on renal prostaglandins for maintenance of renal blood flow (see section 4.2). Treatment with lornoxicam should be discontinued if renal function deteriorates during treatment. &nbsp;</li><li>Renal function should be monitored in patients:<ul><li>Who undergo major surgery &nbsp;</li><li>With cardiac failure&nbsp;</li><li>Receiving concomitant treatment with diuretics or medicinal products that are suspected to, or known to be able to cause kidney damage (see section 4.5).&nbsp;</li></ul></li><li>Patients with blood coagulation disorders: careful clinical monitoring and laboratory assessment is recommended (e.g. APTT).&nbsp;</li><li>Hepatic impairment (e.g. liver cirrhosis): clinical monitoring and laboratory assessments are recommended in patients with hepatic impairment, as accumulation of lornoxicam (increase in AUC) may occur (see section 5.2) after treatment with daily doses of 12 16 mg. Apart from that, hepatic impairment does not seem to affect pharmacokinetic parameters of lornoxicam as compared to healthy subjects. &nbsp;</li><li>In elderly patients above 65 years of age: monitoring of renal and hepatic function is recommended. Caution is advised in elderly postoperative patients.</li></ul><p><strong>Concomitant NSAID use</strong><br />The use of lornoxicam with concomitant NSAIDs (including cyclooxygenase 2 selective inhibitors) should be avoided (see section 4.5).</p><p><strong>Minimisation of undesirable effects</strong><br />Undesirable effects may be minimised by using lowest effective dose for the shortest duration necessary to control symptoms (see section 4.2, and gastrointestinal and cardiovascular risks below).</p><p><strong>Gastrointestinal bleeding, ulceration and perforation</strong><br />Gastrointestinal (GI) bleeding, ulceration and perforation: GI bleeding, ulceration or perforation, which can be fatal, has been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious GI events.</p><p>The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3) and in the elderly. These patients should commence treatment on the lowest dose available (see section 4.2). Combination therapy with gastroprotective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients and also for patients requiring concomitant low dose acetylsalicylic acid or other medicinal products likely to increase gastrointestinal risk (see below and section 4.5). Clinical monitoring at regular intervals is recommended.</p><p>Patients with a history of GI toxicity, particularly the elderly, should be instructed to report any unusual abdominal symptoms (especially GI bleeding) particularly in the initial stages of treatment.&nbsp;</p><p>Caution should be advised in patients receiving concomitant medicinal products, which could increase the risk of ulceration, or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin-reuptake inhibitors or anti-platelet agents such as acetylsalicylic acid (see section 4.5).</p><p>When GI bleeding or ulceration occurs in patients receiving lornoxicam, treatment should be withdrawn.</p><p>NSAIDs should be given with caution to patients with a history of GI disease (e.g. ulcerative colitis, Crohn&rsquo;s disease) as their condition may be exacerbated (see section 4.8).</p><p><strong>Elderly</strong><br />The elderly have an increased frequency of adverse reactions to NSAIDs especially gastrointestinal bleeding and perforation, which may be fatal (see section 4.2).</p><p>Cardiovascular and cerebrovascular effects<br />Appropriate monitoring and advice are required for patients with a history of or present hypertension and/or mild to moderate congestive heart failure, as fluid retention and oedema have been reported in association with NSAID therapy.</p><p>Clinical trial and epidemiological data suggest that use of some NSAIDs, particularly at high doses and in long term treatment, may be associated with an increased risk of arterial thrombotic events (for example myocardial infarction or stroke). There are insufficient data to exclude such a risk for lornoxicam.</p><p>Patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with Lornoxicam after careful consideration. Similar consideration should be made before initiating longer-term treatment of patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking).</p><p>Concomitant treatment with NSAIDs and heparin in the context of a spinal or epidural anaesthesia increases the risk of spinal/epidural haematoma (see section 4.5).</p><p><strong>Skin disorders</strong><br />Serious skin reactions, some of which are fatal, including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), have been reported very rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at highest risk of these reactions early in the course of therapy, the onset of reactions occurring within the first month of treatment in the majority of cases. Lornoxicam should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.</p><p><strong>Respiratory disorders</strong><br />Caution is required if administered to patients suffering from, or with a previous history of, bronchial asthma as NSAIDs have been reported to precipitate bronchospasm in such patients.</p><p><strong>Systemic Lupus Erythematosus and mixed connective tissue disease</strong><br />Caution is required in patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders, as there may be an increased risk of aseptic meningitis.</p><p><strong>Nephrotoxicity</strong><br />Concomitant treatment of NSAIDs and tacrolimus may increase the risk of nephrotoxicity, due to reduced synthesis of prostacyclin in the kidney. Renal function must therefore be monitored closely in patients receiving combination therapy (see section 4.5).</p><p><strong>Laboratory abnormalities</strong><br />As with most NSAIDs, occasional increases in serum transaminases level, increase in serum bilirubin or other liver function parameters, as well as increases in serum creatinine and blood urea nitrogen and other laboratory abnormalities have been reported. Should any such abnormality prove significant or persist the administration of lornoxicam should be stopped and appropriate investigations prescribed.</p><p><strong>Fertility</strong><br />The use of lornoxicam, as with any drug known to inhibit cyclooxygenase / prostaglandin synthesis, may impair fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of lornoxicam should be considered (see section 4.6).</p><p><strong>Varicella</strong><br />Exceptionally, varicella can be at the origin of serious cutaneous and soft tissues infectious complications.&nbsp;</p><p>To date, the contributing role of NSAIDs in the worsening of these infections cannot be ruled out. Thus, it is advisable to avoid use of lornoxicam in case of varicella.&nbsp;</p><p><strong>Xefo contains sodium</strong><br />Xefo contains sodium. Each vial contains 0.027 mg sodium. This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant administration of lornoxicam and</p><ul><li>Cimetidine: Increased plasma concentrations of lornoxicam, which may increase the risk of adverse effects of lornoxicam (No interaction between lornoxicam and ranitidine, or lornoxicam and antacids has been demonstrated).</li><li>Anti-coagulants: NSAIDs may enhance the effects of anti-coagulants, such as warfarin (see section&nbsp;4.4). Careful monitoring of INR should be undertaken.</li><li>Phenprocoumon: Decreased effect of phenprocoumon treatment.</li><li>Heparin: NSAIDs increase the risk of bleeding and spinal or epidural haematomas when given concomitantly to heparin in the context of spinal or epidural anaesthesia (see section&nbsp;4.4).</li><li>ACE inhibitors: The antihypertensive effect of the ACE inhibitor may decrease.</li><li>Diuretics: Decreased diuretic and antihypertensive effect of loop diuretics, thiazide diuretics, and with potassium sparing diuretics (increased risk of hyperkalaemia and nephrotoxicity).</li><li>Beta-adrenergic blockers: Decreased antihypertensive efficacy.</li><li>Angiotensin II receptor blocker: Decreased antihypertensive efficacy.</li><li>Digoxin: Decreased renal clearance of digoxin, which increases risk of digoxin toxicity.</li><li>Corticosteroids: Increased risk of gastrointestinal ulceration or bleeding (see section&nbsp;4.4).</li><li>Quinolone antibiotics (e.g. levofloxacin, ofloxacin): Increased risk of seizures.</li><li>Anti-platelet agents (e.g. clopidogrel): Increased risk of bleeding (see section&nbsp;4.4).</li><li>Other NSAIDs: Increased risk of gastrointestinal bleeding or ulceration.</li><li>Methotrexate: Increased serum concentration of methotrexate. Increased toxicity may result. When concomitant therapy has to be used careful monitoring should be undertaken.</li><li>Selective serotonin reuptake inhibitors (SSRIs): Increased risk of bleeding (see section&nbsp;4.4).</li><li>Lithium: NSAIDs inhibit renal clearance of lithium, thus the serum concentration of lithium may increase above toxicity limits. Therefore serum lithium levels require monitoring, especially during initiation, adjustment and withdrawal of treatment.</li><li>Cyclosporine: Increased serum concentration of cyclosporine. Nephrotoxicity of cyclosporine may be enhanced via renal prostaglandin mediated effects. During combined treatment renal function should be monitored.</li><li>Sulphonylureas (e.g. glibenclamide): Increased risk of hypoglycaemia.</li><li>Known inducers and inhibitors of CYP2C9 isoenzymes: Lornoxicam (as other NSAIDs depending on the cytochrome P450 2C9 (CYP2C9 isoenzyme)) has interactions with known inducers and inhibitors of CYP2C9 isoenzymes (see section&nbsp;5.2 Biotransformation).</li><li>Tacrolimus: Increase the risk of nephrotoxicity owing to reduced synthesis of prostacyclin in the kidney. During combined treatment renal function should be monitored (see section&nbsp;4.4).</li><li>Pemetrexed: NSAIDs may reduce renal clearance of pemetrexed resulting in increased renal and gastrointestinal toxicity, and myelosuppression.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>Lornoxicam is contraindicated in the third trimester of pregnancy (see section 4.3) and should not be used during pregnancy in the first and second trimesters and delivery, as no clinical data on exposed pregnancies are available.</p><p>There are no adequate data from the use of lornoxicam in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3).</p><p>Inhibition of prostaglandin synthesis may adversely affect pregnancy and/or embryo/foetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation after use of a prostaglandin synthesis inhibitor in early pregnancy. The risk is believed to increase with dose and duration of therapy. In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post implantation loss and embryo-foetal lethality. During the first and second trimester of pregnancy, prostaglandin synthesis inhibitors should not be given unless clearly necessary.</p><p>Prostaglandin synthesis inhibitors administered during the third trimester of pregnancy may expose the foetus to cardiopulmonary toxicity (premature closure of the ductus arteriosus and pulmonary hypertension) and renal dysfunction which may lead to renal failure and a reduced quantity of amniotic fluid. At the end of pregnancy, prostaglandin synthesis inhibitors may expose the mother and the foetus to increased bleeding time and inhibition of uterine contractions, which may delay or prolong labour. Therefore, the use of lornoxicam is contraindicated during the third trimester of pregnancy (see section 4.3).</p><p><strong>Breast feeding</strong></p><p>There are no data on the excretion of lornoxicam in human breast milk. Lornoxicam is excreted in milk of lactating rats in relatively high concentrations. Lornoxicam should not be used in breast feeding women.</p><p><strong>Fertility</strong></p><p>The use of lornoxicam, as with any drug known to inhibit cyclooxygenase / prostaglandin synthesis, may impair fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of lornoxicam should be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients showing dizziness and/or somnolence under treatment with lornoxicam should refrain from driving or operation of machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly observed adverse events of NSAIDs are gastrointestinal in nature. Peptic ulcers, perforation or GI bleeding, sometimes fatal, particularly in the elderly, may occur (see section&nbsp;4.4). Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn&rsquo;s disease (see section&nbsp;4.4) have been reported following administration of NSAIDs. Less frequently, gastritis has been observed.</p><p>Approximately 20% of patients treated with lornoxicam can be expected to experience adverse reactions. The most frequent adverse effects of lornoxicam include nausea, dyspepsia, indigestion, abdominal pain, vomiting, and diarrhoea. These symptoms have generally occurred in less than 10% of patients in available studies.</p><p>Oedema, hypertension, and cardiac failure, have been reported in association with NSAID treatment.</p><p>Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with an increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section&nbsp;4.4).</p><p>Exceptionally, occurrence of serious cutaneous and soft tissues infectious complications during varicella.</p><p>Listed below in table 1&nbsp;are undesirable effects, which generally occurred in more than 0.05% of the 6,417&nbsp;patients treated in clinical phase II, III and IV trials.</p><p>The following convention is used for the classification of the frequency of an adverse drug reaction: very common (&sup3;1/10); common (&sup3;1/100 to &lt;1/10); uncommon (&sup3;1/1,000 to &lt;1/100); rare (&sup3;1/10,000 to &lt;1/1.000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p><strong>Table 1: Adverse effects</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:811px"><thead><tr><td style="vertical-align:top; width:223px"><p><strong>System organ class</strong></p></td><td style="vertical-align:top; width:105px"><p><strong>Frequency</strong></p></td><td style="vertical-align:top; width:482px"><p><strong>Adverse reaction(s)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top; width:223px"><p>Infections and infestations</p></td><td style="vertical-align:top; width:105px"><p>Rare</p></td><td style="vertical-align:top; width:482px"><p>Pharyngitis</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:223px"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top; width:105px"><p>Rare</p></td><td style="vertical-align:top; width:482px"><p>Anaemia, thrombocytopenia, leucopenia, prolonged bleeding time</p></td></tr><tr><td style="vertical-align:top; width:105px"><p>Very rare</p></td><td style="vertical-align:top; width:482px"><p>Ecchymosis. NSAIDs have been reported to cause potentially severe haematological disorders like neutropenia, agranulocytosis, aplastic anaemia, and haemolytic anaemia as class effects</p></td></tr><tr><td style="vertical-align:top; width:223px"><p>Immune system disorders</p></td><td style="vertical-align:top; width:105px"><p>Rare</p></td><td style="vertical-align:top; width:482px"><p>Hypersensitivity including anaphylactoid reactions and anaphylaxis</p></td></tr><tr><td style="vertical-align:top; width:223px"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top; width:105px"><p>Uncommon</p></td><td style="vertical-align:top; width:482px"><p>Anorexia, weight changes</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:223px"><p>Psychiatric disorders</p></td><td style="vertical-align:top; width:105px"><p>Uncommon</p></td><td style="vertical-align:top; width:482px"><p>Insomnia, depression</p></td></tr><tr><td style="vertical-align:top; width:105px"><p>Rare</p></td><td style="vertical-align:top; width:482px"><p>Confusion, nervousness, agitation</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:223px"><p>Nervous system disorders</p></td><td style="vertical-align:top; width:105px"><p>Common</p></td><td style="vertical-align:top; width:482px"><p>Mild and transient headache, dizziness</p></td></tr><tr><td style="vertical-align:top; width:105px"><p>Rare</p></td><td style="vertical-align:top; width:482px"><p>Somnolence, paraesthesia, dysgeusia, tremor, migraine</p></td></tr><tr><td style="vertical-align:top; width:105px"><p>Very rare</p></td><td style="vertical-align:top; width:482px"><p>Aseptic meningitis in patients with SLE and mixed connective tissue disorder (see section&nbsp;4.4)</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:223px"><p>Eye disorders</p></td><td style="vertical-align:top; width:105px"><p>Common</p></td><td style="vertical-align:top; width:482px"><p>Conjunctivitis</p></td></tr><tr><td style="vertical-align:top; width:105px"><p>Rare</p></td><td style="vertical-align:top; width:482px"><p>Visual disturbances</p></td></tr><tr><td style="vertical-align:top; width:223px"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top; width:105px"><p>Uncommon</p></td><td style="vertical-align:top; width:482px"><p>Vertigo, tinnitus</p></td></tr><tr><td style="vertical-align:top; width:223px"><p>Cardiac disorders</p></td><td style="vertical-align:top; width:105px"><p>Uncommon</p></td><td style="vertical-align:top; width:482px"><p>Palpitations, tachycardia, oedema, cardiac failure (see section&nbsp;4.4)</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:223px"><p>Vascular disorders</p></td><td style="vertical-align:top; width:105px"><p>Uncommon</p></td><td style="vertical-align:top; width:482px"><p>Flushing, oedema</p></td></tr><tr><td style="vertical-align:top; width:105px"><p>Rare</p></td><td style="vertical-align:top; width:482px"><p>Hypertension, hot flush, haemorrhage, haematoma</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:223px"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top; width:105px"><p>Uncommon</p></td><td style="vertical-align:top; width:482px"><p>Rhinitis</p></td></tr><tr><td style="vertical-align:top; width:105px"><p>Rare</p></td><td style="vertical-align:top; width:482px"><p>Dyspnoea, cough, bronchospasm</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:223px"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top; width:105px"><p>Common</p></td><td style="vertical-align:top; width:482px"><p>Nausea, abdominal pain, dyspepsia, diarrhoea, vomiting</p></td></tr><tr><td style="vertical-align:top; width:105px"><p>Uncommon</p></td><td style="vertical-align:top; width:482px"><p>Constipation, flatulence, eructation, dry mouth, gastritis, gastric ulcer, upper abdominal pain, duodenal ulcer, mouth ulceration</p></td></tr><tr><td style="vertical-align:top; width:105px"><p>Rare</p></td><td style="vertical-align:top; width:482px"><p>Melaena, haematemesis, stomatitis, oesophagitis, gastrooesophageal reflux, dysphagia, aphthous stomatitis, glossitis, perforated peptic ulcer, gastrointestinal haemorrhage</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:223px"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top; width:105px"><p>Uncommon</p></td><td style="vertical-align:top; width:482px"><p>Increase in liver function tests, SGPT (ALT) or SGOT (AST)</p></td></tr><tr><td style="vertical-align:top; width:105px"><p>Very rare</p></td><td style="vertical-align:top; width:482px"><p>Hepatotoxicity resulting in e.g. hepatic failure, hepatitis, jaundice and cholestasis</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:223px"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top; width:105px"><p>Uncommon</p></td><td style="vertical-align:top; width:482px"><p>Rash, pruritus, hyperhidrosis, rash erythematous, urticaria, angioedema, alopecia</p></td></tr><tr><td style="vertical-align:top; width:105px"><p>Rare</p></td><td style="vertical-align:top; width:482px"><p>Dermatitis, eczema, purpura</p></td></tr><tr><td style="vertical-align:top; width:105px"><p>Very rare</p></td><td style="vertical-align:top; width:482px"><p>Oedema and bullous reactions, Stevens‑Johnson syndrome, toxic epidermal necrolysis</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:223px"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top; width:105px"><p>Uncommon</p></td><td style="vertical-align:top; width:482px"><p>Arthralgia</p></td></tr><tr><td style="vertical-align:top; width:105px"><p>Rare</p></td><td style="vertical-align:top; width:482px"><p>Bone pain, muscle spasms, myalgia</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:223px"><p>Renal and urinary disorders</p></td><td style="vertical-align:top; width:105px"><p>Rare</p></td><td style="vertical-align:top; width:482px"><p>Nocturia, micturition disorders, increase in blood urea nitrogen and creatinine levels</p></td></tr><tr><td style="vertical-align:top; width:105px"><p>Very rare</p></td><td style="vertical-align:top; width:482px"><p>Lornoxicam may precipitate acute renal failure in patients with pre‑existing renal impairment, who are dependent on renal prostaglandins for maintenance of renal blood flow (see section&nbsp;4.4). Nephrotoxicity in various forms including nephritis and nephrotic syndrome has been associated with NSAIDs as class effect</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:223px"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top; width:105px"><p>Uncommon</p></td><td style="vertical-align:top; width:482px"><p>Malaise, face oedema</p></td></tr><tr><td style="vertical-align:top; width:105px"><p>Rare</p></td><td style="vertical-align:top; width:482px"><p>Asthenia</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&bull;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States</p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>At this time, there is no experience of overdose to permit definition of the consequence of an overdose, or to suggest specific management. However, it can be expected that after an overdose with lornoxicam, the following symptoms may be observed: nausea, vomiting, cerebral symptoms (dizziness, disturbances in vision). Severe symptoms such as ataxia (ascending to coma and cramps), liver and kidney damage and potentially coagulation disorders may also occur.</p><p>In the case of a real or suspected overdose, the medicinal product should be withdrawn. Due to its short half-life, lornoxicam is rapidly excreted. Lornoxicam is not dialysable. No specific antidote is known to date. Gastrointestinal disorders can for example be treated with a prostaglandin analogue or ranitidine.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Anti-inflammatory and antirheumatic products, non-steroids, oxicams.</p><p>ATC code: M01 AC05.</p><p><strong>Mechanism of action</strong></p><p>Lornoxicam is a non-steroidal anti-inflammatory drug with analgesic properties and belongs to the class of oxicams. Lornoxicams mode of action is mainly related to inhibition of prostaglandin synthesis (inhibition of cyclooxygenase enzyme), leading to desensitisation of peripheral nociceptors and consequently inhibition of inflammation. A central effect on nociception, which seems to be independent of anti‑inflammatory effects has also been suggested.</p><p><strong>Pharmacodynamic effects</strong></p><p>Lornoxicam has no effect on vital signs (e.g. body temperature, respiratory rate, heart rate, blood pressure, ECG, spirometry).</p><p><strong>Clinical efficacy and safety</strong></p><p>The analgesic properties of lornoxicam have been demonstrated successfully in several clinical trials during development of the drug.</p><p>Due to a local gastrointestinal irritation and a systemic ulcerogenic effect related to the inhibition of prostaglandin (PG)-synthesis, gastrointestinal sequela are common undesirable effects after treatment with lornoxicam as seen with other NSAIDs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong></p><p>Lornoxicam 8 mg powder for injection is intended for intravenous (IV) as well as intramuscular (IM) administration. After IM injection, maximum plasma concentrations are achieved after approximately 0.4 hours. The absolute bioavailability (calculated on AUC) after IM administration is 97%.</p><p><strong>Distribution</strong></p><p>Lornoxicam is found in the plasma in unchanged form and as its hydroxylated metabolite. The plasma protein binding of lornoxicam is 99% and not concentration dependent. It is also found in synovial fluid after repeated dosing.</p><p><strong>Biotransformation</strong></p><p>Lornoxicam is extensively metabolised in the liver, primarily to the inactive 5-hydroxylornoxicam by hydroxylation. CYP2C9 is involved in biotransformation of lornoxicam. Due to genetic polymorphism, slow and extensive metabolisers exist for this enzyme, which could result in markedly, increased plasma levels of lornoxicam in slow metabolisers. The hydroxylated metabolite exhibits no pharmacological activity. Lornoxicam is metabolised completely, and approximately 2/3 is eliminated via the liver and 1/3 via the kidneys as inactive substance.</p><p>When tested in animal models, lornoxicam did not induce liver enzymes. From clinical trial data there is no evidence of accumulation of lornoxicam after repeated administrations, when given according to recommended dosage. This finding was supported by drug monitoring data from one year studies.</p><p><strong>Elimination</strong></p><p>The mean elimination half-life of the parent compound is 3 to 4 hours. After oral administration about 50% is excreted in the faeces and 42% through the kidneys, mainly as 5-hydroxylornoxicam. The elimination half-life of 5-hydroxylornoxicam is approximately 9 hours after a parenteral single or twice daily dose. There is no evidence that elimination rate changes with repeat dose administration.</p><p>In elderly patients above age 65, the clearance is reduced with 30-40%. Apart from reduced clearance, there is no significant change in the kinetic profile of lornoxicam in elderly patients.</p><p>There is no significant change in the kinetic profile of lornoxicam in patients with renal or hepatic failure, except for accumulation in patients with chronic liver disease after 7 days of treatment with daily doses of 12 and 16 mg.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazards for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential.</p><p>Lornoxicam has caused renal toxicity and gastrointestinal ulceration in single- and repeat-dose toxicity studies in several species.</p><p>In rats, lornoxicam has impaired fertility (effects on ovulation and implantation), and affected pregnancy and delivery. In rabbits and rats, lornoxicam has caused premature closure of the ductus arteriosus due to inhibition of cyclooxygenase.</p><p>In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post- implantation loss and embryo-foetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Powder</em> (<em>vial):</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Mannitol</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Trometamol</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Disodium edetate.</p><p><em>Solvent</em> (<em>ampoule):</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.  

Reconstituted solution: Chemical and physical in-use stability has been demonstrated for 24 hours at 21°C (±2°C).

From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use is the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C unless reconstitution/dilution has taken place in controlled and validated aseptic conditions.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&deg;C.</p><p>Store in the original package in order to protect from light.</p><p>For storage conditions of the reconstituted medicinal product, see section&nbsp;6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vials: Amber glass (class I) vials with rubber stoppers, sealed with aluminium snap-off closures.</p><p>Ampoules: Clear glass ampoules.</p><p>Pack size: 1 Vial + 1 Ampoule (2 ml water for injection).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The solution for injection is prepared by dissolving the content of one vial in water for injection from the accompanying ampoule, immediately prior to use. The appearance of the product after reconstitution is a yellow, clear liquid.</p><p>If visible signs of deterioration are seen in the medicinal product, the product must be disposed of in accordance with local requirements</p><p>Lornoxicam has shown compatibility with 0.9% NaCl, 5% dextrose (glucose) and Ringer&rsquo;s solution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. Box 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                15 June 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>